Unlocking the therapeutic potential of PPAR signaling
Fibrosis, metabolic conditions and oncology
ABOUT INNOSPERA PHARMA
Innospera is a privately held, clinical-stage biotechnology company developing small-molecule, lipid-mimetic PPAR potentiators for chronic and fibrotic diseases.
PPARs* are clinically validated targets in fibro-inflammatory disease; ING-006 engages them by a new route, acting at a distinct site to sensitize the receptor and deepen a signaling axis that is anti-fibrotic by nature.
Building on the clinical precedent established by other PPAR agonists, ING-006 combines a markedly improved pharmacological profile with an anticipated broad safety margin and favorable tolerability.
The Company's pipeline includes additional PPAR potentiators addressing cardiometabolic and other chronic conditions.
*PPARs: Peroxisome Proliferator-Activated Receptors
Leadership team
François Ravenelle, PhD
President and CEO
Glenn Crater, MD, FCCP
CMO
Lyne Gagnon, PhD
CSO and Co-Founder
Pierre Laurin, BPharm, MSc
COO and Co-Founder
Board of Directors
Pierre Laurin BPharm, MSc
Executive Chairman, COO and co-founder, Innospera
François Ravenelle PhD
President and CEO Innospera
Micheline Beauvais CPA, MBA
Ex-CEO
Inversago Pharma
Patricia Escoffier PhD
Principal
Seido Capital
Hélène Moore MBA
Director
Anges Québec
Denis Garceau BPharm, PhD
Ex-CSO
Bellus Health
Hubert Sibre LLB
Partner
Miller Thomson
Maxime Daigle CPA
Board Observer, Director, Investissement Québec
Our lead product: ING-006
First-in-class PPAR Potentiator to Restore Downregulated Biology in IPF
THERAPEUTIC STRATEGY
IPF is characterized by reduced PPAR expression and activity:
-
driven by TGF-ß-induced transcriptional suppression
-
compounded by a disrupted lipid profile that depletes endogenous PPAR ligands
Low PPAR activity
removes a brake on TGF-ß signaling, leading also to an upregulation of GPR84.
RESTORING PPAR ACTIVITY
ING-006 is a PPAR potentiator.
By allosterically binding to PPARs, ING-006 potentiates the activity
of orthosteric PPAR agonists, including its own main metabolite which is a known pan-PPAR partial agonist.
ING-006 only restores what is lost.
Healthy tissues appear spared—a key driver of the exceptional tolerability and safety profile.
DE-RISKED CLINICAL DEVELOPMENT
In addition to its allosteric PPAR activity, one of ING-006 metabolites is also an orthosteric PPAR agonist with demonstrated safety and activity in phase 2 clinical trials.
ING-006 presents an excellent toxicology profile with high safety margin, and is well tolerated in healthy volunteers in the on-going phase 1 clinical trial.
Our Pipeline
ING-008 and ING-Series: Expanding the Lipid-Mimetic Platform
Next-generation lipid-mimetics
Analogues of prior clinical and preclinical fatty acid products, designed with differentiated PPAR agonist/modulation, potencies and unique DMPK properties.
Organ- and indication-specific potential
Opportunity to target new tissues and diseases while maintaining the strong safety/tolerability profile of the class.
Pipeline expansion
Multiple candidates under evaluation.
